{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:03:00Z","timestamp":1787022180158,"version":"build-2736575974"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing global prevalence of mental disorders as well as a persistent stigma make mental disorders a public health priority. The aim of this study was to provide a comprehensive overview of psychotropic drugs utilization from 2006 to 2021 in the Republic of Serbia, examining both pre pandemic and pandemic-related changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To conduct this descriptive study, publicly available data on psychotropic drugs were retrieved from the official website of the Agency for Medicines and Medical Devices of Serbia (ALIMS). The linear and joinpoint regression were used in data analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 54 psychotropic drugs use was analyzed from 2006 to 2021. There was an increase in the consumption of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoid-based drugs. The increase in the consumption of the psychotropic drugs was linear, with no differences between the pre-COVID-19 period and the COVID-19 pandemic. Contrary, a significant decrease in use was observed for some antidepressants (maprotiline, moclobemide, mianserin), antipsychotics (chlorpromazine, fluphenazine), psychostimulants and nootropic drugs (piracetam), anxiolytics (diazepam, prazepam), sedatives and hypnotics (midazolam).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The COVID-19 pandemic did not contribute to change in consumption of psychotropic drugs in Serbia. Still, the use of antidepressants, atypical antipsychotics, anxiolytics, sedatives, hypnotics, anti-dementia drugs and gabapentinoids increased from 2006 to 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0330749","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:40:01Z","timestamp":1758735601000},"page":"e0330749","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic"],"prefix":"10.1371","volume":"20","author":[{"given":"Jelena","family":"Filimonovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Stevanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9621-8375","authenticated-orcid":true,"given":"Tatjana","family":"Gazibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Saponjic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Dotlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perisa","family":"Simonovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vukajlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Stojanovic Tasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Joksimovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Stosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miljan","family":"Adamovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Jelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Perovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Nastic Simovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Adamovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasija","family":"Karapandzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajana","family":"Nogo Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorica","family":"Stanojevic Ristic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5575-0587","authenticated-orcid":true,"given":"Marija","family":"Milic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"pone.0330749.ref001","unstructured":"Institute for Public Health of Serbia \u201cDr. Milan Jovanovic Batut\u201d. Research on the health of the population of Serbia in 2019. Republic Institute of Statistics. Available from: https:\/\/batut.org.rs\/index.php?content=2227"},{"key":"pone.0330749.ref002","unstructured":"UNICEF for every child. Mental Health and Well-being. [cited Apr 23 2023] Available from: https:\/\/www.unicef.org\/serbia\/en\/mental-health-and-well-being"},{"issue":"12","key":"pone.0330749.ref003","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S2215-0366(21)00292-3","article-title":"Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study","volume":"8","author":"R Brauer","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"pone.0330749.ref004","unstructured":"World Health Organization. Mental Health - action plan 2013-2020. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/89966\/9789241506021_eng.pdf;jsessionid=DE30D70A5203071D6B0BD04B70D4B377?sequence=1"},{"issue":"2","key":"pone.0330749.ref005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2215-0366(20)30482-X","article-title":"Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study","volume":"8","author":"D Fancourt","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"pone.0330749.ref006","unstructured":"OEDC. Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. Available from: https:\/\/oecd.org\/coronavirus\/policy-responses\/tackling-the-mental-health-impact-of-the-covid-19-crisis-an-integrated-whole-of-society-response-0ccafa0b\/"},{"issue":"1","key":"pone.0330749.ref007","doi-asserted-by":"crossref","first-page":"19336","DOI":"10.1038\/s41598-022-22085-4","article-title":"Psychotropic drug purchases during the COVID-19 pandemic in Italy and their relationship with mobility restrictions","volume":"12","author":"F Marazzi","year":"2022","journal-title":"Sci Rep"},{"issue":"10312","key":"pone.0330749.ref008","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","journal-title":"Lancet"},{"issue":"43","key":"pone.0330749.ref009","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027664","article-title":"Psychotropic medication prescribing during the COVID-19 pandemic","volume":"100","author":"ME Hirschtritt","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"pone.0330749.ref010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/09540261.2012.699450","article-title":"State of psychiatry in Serbia--problems, advances and perspectives","volume":"24","author":"DL Tosevski","year":"2012","journal-title":"Int Rev Psychiatry"},{"issue":"7","key":"pone.0330749.ref011","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.3390\/ijerph20075321","article-title":"Psychological Distress in the Republic of Serbia, the Association of Social Characteristics and Substance Use on a National Representative Sample of Serbia","volume":"20","author":"M Tadic","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0330749.ref012","first-page":"750","article-title":"Impact of Differences in Economic Development and Socioeconomic Stability on Benzodiazepine Exposure between the Three Balkans Countries","volume":"31","author":"SZ Markovi\u0107","year":"2019","journal-title":"Psychiatr Danub"},{"issue":"2","key":"pone.0330749.ref013","first-page":"126","article-title":"Trends in consumption and use of antidepressants and benzodiazepines in the Republic of Serbia in the period 2006-2019","volume":"96","author":"A Medarevi\u0107","year":"2022","journal-title":"Serbian J Public Health"},{"key":"pone.0330749.ref014","unstructured":"Medicines and Medical Devices Agency of Serbia (ALIMS). Trade and consumption of medicines for human use in Republic of Serbia in 2020. Available from: https:\/\/www.alims.gov.rs\/wp-content\/uploads\/2022\/08\/PROMET-HUMANIH-2020-PUBLIKACIJA-1.pdf[Serbian]"},{"key":"pone.0330749.ref015","unstructured":"World Health Organization. Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2023. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"pone.0330749.ref016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-0327(01)00355-X","article-title":"Redefining mood stabilization","volume":"73","author":"PE Jr Keck","year":"2003","journal-title":"J Affect Disord"},{"issue":"1","key":"pone.0330749.ref017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.ajp.161.1.3","article-title":"What is a \u201cmood stabilizer\u201d? An evidence-based response","volume":"161","author":"MS Bauer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"pone.0330749.ref018","unstructured":"World Health Organization. Defined Daily Dose (DDD). Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd"},{"key":"pone.0330749.ref019","unstructured":"National Cancer Institute. Joinpoint trend analysis software. [cited Mar 21, 2023]. Available from: https:\/\/surveillance.cancer.gov\/joinpoint\/"},{"key":"pone.0330749.ref020","unstructured":"Centers for Disease Control and Prevention. Joinpoint trend analysis software. 2020-2021. [cited Sep 19, 2023]. Available from: https:\/\/www.cdc.gov\/nchs\/hus\/sources-definitions\/joinpoint.htm"},{"issue":"9","key":"pone.0330749.ref021","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/pds.3255","article-title":"Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009","volume":"21","author":"C-S Wu","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pone.0330749.ref022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/00048674221079740","article-title":"Changes in antidepressant use in Australia: A nationwide analysis (2015-2021)","volume":"57","author":"J de Oliveira Costa","year":"2023","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"pone.0330749.ref023","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1192\/bjp.bp.114.156786","article-title":"Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors","volume":"207","author":"D Lewer","year":"2015","journal-title":"Br J Psychiatry"},{"key":"pone.0330749.ref024","unstructured":"National Institute for Health and Care Excellence Depression in adults: treatment and management. NICE guideline: short version (update NICE guideline CG90). [cited May 12, 2020]. Available from: https:\/\/www.nice.org.uk\/guidance\/GID-CGWAVE0725\/documents\/short-version-of-draft-guideline"},{"key":"pone.0330749.ref025","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"DM Taylor","year":"2018","edition":"13"},{"issue":"1","key":"pone.0330749.ref026","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5937\/hpimj1801607M","article-title":"Analysis of antidepressant use in Republic of Serbia from 2013 to 2015","volume":"5","author":"\u017d Milija\u0161evi\u0107 B","year":"2018","journal-title":"Hosp Pharm Int Multi J"},{"issue":"1","key":"pone.0330749.ref027","first-page":"9","article-title":"Mental health protection in serbia - challenges and solutions National Commission for Mental Health, Ministry of Health of the Republic of Serbia, Belgrade","volume":"37","author":"D Lecic Tosevski","year":"2005","journal-title":"Psihijat dan"},{"issue":"10324","key":"pone.0330749.ref028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(22)00187-8","article-title":"Depression and anxiety during COVID-19","volume":"399","author":"M Daly","year":"2022","journal-title":"Lancet"},{"key":"pone.0330749.ref029","volume-title":"The implications of COVID-19 for mental health and substance use","author":"N Panchal","year":"2023"},{"key":"pone.0330749.ref030","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796022000117","article-title":"Covid-19-related stressors, mental disorders, depressive and anxiety symptoms: a cross-sectional, nationally-representative, face-to-face survey in Serbia","volume":"31","author":"NP Mari\u0107","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"10","key":"pone.0330749.ref031","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: A study in 16 countries, 2005-2014","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"pone.0330749.ref032","unstructured":"ALIMS. Summary of drug characteristics, Onzapine. Available from: http:alims.gov.rs\/doc_file\/lekovi\/smpc\/515-01-00-225-20-202.pdf"},{"key":"pone.0330749.ref033","unstructured":"ALIMS. Summary of drug characteristics, Q-PIN. Available from: http:alims.gov.rs\/doc_file\/lekovi\/smpc\/515\u201301-01950\u201316-001.pdf"},{"key":"pone.0330749.ref034","unstructured":"ALIMS. Summary of drug characteristics, Xeplion. Available from: http:alims.gov.rs\/doc_file\/lekovi\/smpc\/515-01-03164-17-01.pdf"},{"issue":"10202","key":"pone.0330749.ref035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet"},{"key":"pone.0330749.ref036","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2020.11.057","article-title":"Temporal trends in psychotic symptoms: Repeated cross-sectional surveys of the population in England 2000-14","volume":"228","author":"N Shoham","year":"2021","journal-title":"Schizophr Res"},{"issue":"6","key":"pone.0330749.ref037","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/00048674211025716","article-title":"The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia","volume":"56","author":"S Kisely","year":"2022","journal-title":"Aust N Z J Psychiatry"},{"key":"pone.0330749.ref038","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jad.2022.11.068","article-title":"Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia","volume":"323","author":"M Tiger","year":"2023","journal-title":"J Affect Disord"},{"issue":"22","key":"pone.0330749.ref039","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.3390\/ijerph17228612","article-title":"The Use of Antidepressants, Anxiolytics, Sedatives and Hypnotics in Europe: Focusing on Mental Health Care in Portugal and Prescribing in Older Patients","volume":"17","author":"M Estrela","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"pone.0330749.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284389","article-title":"Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries","volume":"18","author":"O Alabaku","year":"2023","journal-title":"PLoS One"},{"key":"pone.0330749.ref041","article-title":"Sedative-hypnotic drugs.","volume-title":"Basic & Clinical Pharmacology","author":"AJ Trevor","year":"2021","edition":"15"},{"key":"pone.0330749.ref042","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jad.2022.07.017","article-title":"Benzodiazepines consumption may have increased during the COVID-19 pandemic","volume":"314","author":"C Mattiuzzi","year":"2022","journal-title":"J Affect Disord"},{"key":"pone.0330749.ref043","unstructured":"mhGAP: Mental Health Gap Action Programme: Scaling Up Care for Mental, Neurological and Substance Use Disorders."},{"issue":"2","key":"pone.0330749.ref044","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/WAD.0000000000000357","article-title":"Trends in the Use of Medications and Supplements to Treat or Prevent Dementia: A Population-based Study","volume":"34","author":"GP Stoehr","year":"2020","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"pone.0330749.ref045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2298\/SARH200504028S","article-title":"Perspectives on mental health services during the COVID-19 epidemic in Serbia","volume":"148","author":"I Stasevic-Karlicic","year":"2020","journal-title":"Srp Arh Celok Lek"},{"issue":"5","key":"pone.0330749.ref046","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10072-022-06586-8","article-title":"Anti-dementia drugs: a descriptive study of the prescription pattern in Italy","volume":"44","author":"I Ippoliti","year":"2023","journal-title":"Neurol Sci"},{"issue":"1","key":"pone.0330749.ref047","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12889-023-16051-6","article-title":"Misuse of Pregabalin: a qualitative study from a patient\u2019s perspective","volume":"23","author":"L Servais","year":"2023","journal-title":"BMC Public Health"},{"key":"pone.0330749.ref048","unstructured":"ALIMS. Summary of drug characteristics, Pregabalin. Available from: https:\/\/www.alims.gov.rs\/doc_file\/lekovi\/smpc\/515-01-04662-18-001.pdf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:40:14Z","timestamp":1758735614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330749"}},"subtitle":[],"editor":[{"given":"Ioannis","family":"Liampas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330749","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}